StockWaves
  • Home
  • Global Markets
    Global MarketsShow More
    Will I make extra from placing £2k in progress shares or revenue shares proper now?
    Will I make extra from placing £2k in progress shares or revenue shares proper now?
    4 Min Read
    Largest inventory movers Monday: XYZ, and extra (NYSE:XYZ)
    Largest inventory movers Monday: XYZ, and extra (NYSE:XYZ)
    0 Min Read
    Asia inventory markets right this moment: stay updates
    Asia inventory markets right this moment: stay updates
    7 Min Read
    Carmaker Stellantis sees H1 internet lack of .7 billion hit by restructuring prices
    Carmaker Stellantis sees H1 internet lack of $2.7 billion hit by restructuring prices
    0 Min Read
    Is the S&P 500 heading in direction of a market crash?
    Is the S&P 500 heading in direction of a market crash?
    5 Min Read
  • Investment Strategies
    Investment StrategiesShow More
    GMDC cools off after a fiery rally
    GMDC cools off after a fiery rally
    0 Min Read
    Fortis Healthcare Ltd — Shaping India’s Subsequent-Gen CareInsights
    Fortis Healthcare Ltd — Shaping India’s Subsequent-Gen CareInsights
    10 Min Read
    Waaree Renewables slips 5% after Assam challenge cancellation
    Waaree Renewables slips 5% after Assam challenge cancellation
    0 Min Read
    Mutual Funds Investing Keep away from Frequent Errors & Construct a Resilient Portfolio
    Mutual Funds Investing Keep away from Frequent Errors & Construct a Resilient Portfolio
    25 Min Read
    Prime information and market movers this week: 18th Jul’ 2025
    Prime information and market movers this week: 18th Jul’ 2025
    2 Min Read
  • Market Analysis
    Market AnalysisShow More
    JSW Metal dips regardless of 109% rise in Q1 internet revenue
    JSW Metal dips regardless of 109% rise in Q1 internet revenue
    0 Min Read
    UltraTech Cement Q1 Outcomes: Revenue surges 49% YoY to ₹2226 crore; income up 13%
    UltraTech Cement Q1 Outcomes: Revenue surges 49% YoY to ₹2226 crore; income up 13%
    1 Min Read
    Anthem Biosciences pops 27% on debut. However is it too expensive?
    Anthem Biosciences pops 27% on debut. However is it too expensive?
    0 Min Read
    HDFC Financial institution’s Bonus Shares and Particular Interim Dividend Introduced
    HDFC Financial institution’s Bonus Shares and Particular Interim Dividend Introduced
    11 Min Read
    Poonawalla Fincorp shares rise after fundraise transfer. Particulars right here
    Poonawalla Fincorp shares rise after fundraise transfer. Particulars right here
    4 Min Read
  • Trading
    TradingShow More
    Verizon Gears Up For Q2 Print; Right here Are The Current Forecast Modifications From Wall Avenue’s Most Correct Analysts – Verizon Communications (NYSE:VZ), Nokia (NYSE:NOK)
    Verizon Gears Up For Q2 Print; Right here Are The Current Forecast Modifications From Wall Avenue’s Most Correct Analysts – Verizon Communications (NYSE:VZ), Nokia (NYSE:NOK)
    3 Min Read
    Tim Burchett Shrugs Off Trump’s ‘Silly’ Comment, Doubles Down On Jeffrey Epstein Recordsdata Push: ‘Does not Give Up Its Secrets and techniques Very Straightforward’
    Tim Burchett Shrugs Off Trump’s ‘Silly’ Comment, Doubles Down On Jeffrey Epstein Recordsdata Push: ‘Does not Give Up Its Secrets and techniques Very Straightforward’
    3 Min Read
    Jamie Dimon Reveals A Espresso Desk Chat With Jeff Bezos In 1999 That Nearly Made Him ‘By no means Put on A Go well with Once more…Stay On A Houseboat’
    Jamie Dimon Reveals A Espresso Desk Chat With Jeff Bezos In 1999 That Nearly Made Him ‘By no means Put on A Go well with Once more…Stay On A Houseboat’
    3 Min Read
    ‘Superman’ Flies Previous 0 Million However Falters Abroad, Whereas ‘Jurassic World Rebirth’ Prices Towards 0 Million In A Purple-Scorching Summer season Field Workplace Battle – Apple (NASDAQ:AAPL), Comcast (NASDAQ:CMCSA)
    ‘Superman’ Flies Previous $400 Million However Falters Abroad, Whereas ‘Jurassic World Rebirth’ Prices Towards $650 Million In A Purple-Scorching Summer season Field Workplace Battle – Apple (NASDAQ:AAPL), Comcast (NASDAQ:CMCSA)
    4 Min Read
    Elon Musk Returns To Intense Work Schedule: ‘Again To Working 7 Days a Week and Sleeping within the Workplace’
    Elon Musk Returns To Intense Work Schedule: ‘Again To Working 7 Days a Week and Sleeping within the Workplace’
    2 Min Read
Reading: An Interview with Dr. Divneet Kaur, CEO of Dermabay
Share
Font ResizerAa
StockWavesStockWaves
  • Home
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading
Search
  • Home
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading
Follow US
2024 © StockWaves.in. All Rights Reserved.
StockWaves > Business > An Interview with Dr. Divneet Kaur, CEO of Dermabay
Business

An Interview with Dr. Divneet Kaur, CEO of Dermabay

StockWaves By StockWaves Last updated: July 16, 2025 7 Min Read
An Interview with Dr. Divneet Kaur, CEO of Dermabay
SHARE


Contents
An Interview with Dr. Divneet Kaur, a Pharmaceutical Scientist, Co-Founder & CEO of Dermabay, a science-first, formulation-led Indian skincare modelAre you able to share your journey into the pharmaceutical business and what impressed you to co-found Dermabay?What distinctive challenges did you face whereas establishing Dermabay, and the way did you overcome them?Are you able to focus on the analysis and improvement course of behind Dermabay’s merchandise?How does Dermabay differentiate itself from different firms within the pharmaceutical and skincare sectors?How do you guarantee the protection and efficacy of your merchandise throughout the improvement course of?How do you method collaboration with different scientists and researchers within the area?What recommendation would you give to aspiring entrepreneurs within the pharmaceutical business?

An Interview with Dr. Divneet Kaur, a Pharmaceutical Scientist, Co-Founder & CEO of Dermabay, a science-first, formulation-led Indian skincare model

In an unique interview, we converse with Dr. Divneet Kaur, Co-Founder & CEO of Dermabay, a science-first, formulation-led Indian skincare model. Discover her journey and imaginative and prescient for revolutionary magnificence.

Are you able to share your journey into the pharmaceutical business and what impressed you to co-found Dermabay?

Dr. Divneet Kaur: I entered pharmaceutical sciences to specialise in drug supply programs and transdermal peptide applied sciences. The most important subject I noticed throughout my time working throughout analysis labs and mentoring college students was the growing disconnect between scientific breakthroughs and client accessibility of skincare merchandise.

I skilled many requests from folks in my setting about their skincare merchandise failing to ship regardless of their costly pricing and worldwide origins. That was my turning level.

The scientific group in India possessed all mandatory data however did not translate analysis into sensible skincare options. This discovery remodeled into the inspiration that created Dermabay.

What distinctive challenges did you face whereas establishing Dermabay, and the way did you overcome them?

Dr. Divneet Kaur: The most important impediment we confronted was staying away from widespread practices of latest skincare manufacturers which concerned white-labeling or blindly following the traits.

Our firm made an intentional resolution to supply each components internally by conducting thorough testing and taking full accountability for our provide chain administration.

We pursued this method to make sure formulation integrity on the expense of prolonged manufacturing timelines and elevated prices.

The primary problem concerned educating customers in regards to the significance of ingredient transparency and stability alongside bioavailability. We achieved this by telling tales primarily based on scientific details as a substitute of utilizing promotional gimmicks.

Are you able to focus on the analysis and improvement course of behind Dermabay’s merchandise?

Dr. Divneet Kaur: Each product begins with figuring out its scientific goal which incorporates understanding the problem-solution and the actives that present effectiveness below Indian situations.

Our R&D group comprising of pharmaceutical marvels and dermatology consultants begins by growing prototypes which mix steady molecules with optimized absorption patterns and organic compatibility.

Our group then conducts successive rounds of inner product testing which results in modifications primarily based on prompt suggestions. The lengthy deliberate improvement course of allows us to construct skincare merchandise that ship efficiency slightly than traits.

How does Dermabay differentiate itself from different firms within the pharmaceutical and skincare sectors?

Dr. Divneet Kaur: Dermabay connects pharmaceutical-grade formulation to skin-first empathy. Our firm focuses on utilizing imported energetic elements along with advertising tales for skincare merchandise as a result of we think about medical perform alongside indigenous formulation design and long-term pores and skin compatibility.

We don’t promote routines—they’re remodeled into tangible outcomes. Our dedication to scientific excellence and sincere communication about pores and skin well being has remained fixed from our humble beginnings to working with main dermatologists in India.

Our genuine model identification mixed with our full management over formulation mental property makes us distinctive out there.

How do you guarantee the protection and efficacy of your merchandise throughout the improvement course of?

Dr. Divneet Kaur: Our formulations obtain the identical degree of consideration as drug molecules throughout the improvement course of. We prioritize security and efficacy collectively by following these important ideas:

  • Ingredient sourcing from verified suppliers
  • Energetic focus primarily based on medical data
  • Stability testing in assorted Indian temperatures and humidity ranges
  • Patch testing for sensitivity and irritation
  • Compliance with regulatory and dermatological requirements

We check new merchandise on precise customers in managed settings earlier than releasing them into market. All merchandise have to show their efficiency on actual Indian pores and skin by means of knowledge proof and safe confidence earlier than they are often launched to the general public.

How do you method collaboration with different scientists and researchers within the area?

Dr. Divneet Kaur: We contemplate collaboration to be an important obligation as a substitute of an elective selection. Our firm conducts common consultations with dermatologists together with beauty chemists and pharmacologists to enhance our formulation strategies.

Our product prototypes obtain steady suggestions from exterior researchers all through the event course of.

I preserve common contact with educational establishments whereas mentoring younger researchers as a result of I consider scientists ought to work collectively as a substitute of competing towards one another.

What recommendation would you give to aspiring entrepreneurs within the pharmaceutical business?

Dr. Divneet Kaur: Construct for depth, not velocity. Pharmaceutical science requires scientists to show persistence and precision and to keep up a humble method to their work.

Actual-world impact takes priority over fast market entry. Your group ought to embody consultants who each perceive scientific ideas and client wants.

The method of innovation turns into profitable by means of your capability to simplify advanced concepts into easy-to-understand ideas and develop options that deal with real-world issues.

Your credibility capabilities as your monetary useful resource so you could defend it towards any potential threats.

Dr. Kaur’s insights illuminate Dermabay’s dedication to efficient, evidence-based skincare. Her imaginative and prescient empowers customers with scientifically crafted merchandise, shaping the way forward for Indian magnificence.



Are you an
Entrepreneur or Startup?


Do you’ve a Success Story to Share?

SugerMint wish to share your success story.
We cowl entrepreneur Tales, Startup Information, Ladies entrepreneur tales, and Startup tales


Discover Success story of Indian entrepreneurs & startups at SugerMint. Comply with us on Twitter, Instagram, Fb, LinkedIn



Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Previous Article Asian shares decline: Asian shares decline as Fed price lower bets wane Asian shares decline: Asian shares decline as Fed price lower bets wane
Next Article Mike Johnson Breaks Ranks With Trump On The ‘Very Delicate Topic’ Of Epstein: ‘I am For Transparency’ – Tesla (NASDAQ:TSLA) Mike Johnson Breaks Ranks With Trump On The ‘Very Delicate Topic’ Of Epstein: ‘I am For Transparency’ – Tesla (NASDAQ:TSLA)
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow

Subscribe Now

Subscribe to our newsletter to get our newest articles instantly!

Most Popular
Is Gurgaon’s Actual Property Bubble Actual—or Only a Shift in Purchaser Psychology?
Is Gurgaon’s Actual Property Bubble Actual—or Only a Shift in Purchaser Psychology?
July 21, 2025
Will I make extra from placing £2k in progress shares or revenue shares proper now?
Will I make extra from placing £2k in progress shares or revenue shares proper now?
July 21, 2025
JSW Metal dips regardless of 109% rise in Q1 internet revenue
JSW Metal dips regardless of 109% rise in Q1 internet revenue
July 21, 2025
Watch: Air Power coaching jet crashes into college in Bangladesh’s Dhaka
Watch: Air Power coaching jet crashes into college in Bangladesh’s Dhaka
July 21, 2025
PCBL Shares Surge 1% with Patent Approval Replace
PCBL Shares Surge 1% with Patent Approval Replace
July 21, 2025

You Might Also Like

An Interview with Sidhhant Agarwal, CEO of SportVot
Business

An Interview with Sidhhant Agarwal, CEO of SportVot

7 Min Read
“All IPL franchises to name their overseas gamers to return”: BCCI sources
Business

“All IPL franchises to name their overseas gamers to return”: BCCI sources

3 Min Read
High 10 Upcoming Bollywood Motion pictures Releasing In March 2025
Business

High 10 Upcoming Bollywood Motion pictures Releasing In March 2025

9 Min Read
India: Asia’s Deep Tech Powerhouse
Business

India: Asia’s Deep Tech Powerhouse

7 Min Read

Always Stay Up to Date

Subscribe to our newsletter to get our newest articles instantly!

StockWaves

We provide tips, tricks, and advice for improving websites and doing better search.

Latest News

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service

Resouce

  • Blockchain
  • Business
  • Economics
  • Financial News
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading

Trending

Is Gurgaon’s Actual Property Bubble Actual—or Only a Shift in Purchaser Psychology?
Will I make extra from placing £2k in progress shares or revenue shares proper now?
JSW Metal dips regardless of 109% rise in Q1 internet revenue

2024 © StockWaves.in. All Rights Reserved.

Welcome Back!

Sign in to your account

Not a member? Sign Up